Literature DB >> 7357948

Cardiopulmonary effects of fenoterol and salbutamol aerosols.

M K Tandon.   

Abstract

Comparative evaluation of the bronchodilator and cardiovascular effects of cumulative dose of fenoterol and salbutamol (albuterol) aerosols was carried out in an open crossover study on 15 patients with chronic stable reversible airways obstruction. On a weight for weight basis, there was no significant difference in the bronchodilator efficacy of fenoterol and salbutamol; though the heart rates after fenoterol were significantly higher than after salbutamol. Ventricular dysrhythmias requiring premature cessation of the study in four patients were seen with fenoterol; whereas no significant ventricular dysrhythmias were observed with salbutamol. It is concluded that salbutamol has lesser cardiostimulatory effects than fenoterol.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357948     DOI: 10.1378/chest.77.3.429

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.

Authors:  M Scheinin; M Koulu; E Laurikainen; H Allonen
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

2.  Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers.

Authors:  Manpreet K Virk; Justin Hotz; Robinder G Khemani; Christopher J L Newth; Patrick A Ross
Journal:  Lung       Date:  2017-02-16       Impact factor: 2.584

3.  Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

Authors:  J Crane; C Burgess; R Beasley
Journal:  Thorax       Date:  1989-02       Impact factor: 9.139

Review 4.  The current debate concerning beta-agonists in asthma: a review.

Authors:  K F Chung
Journal:  J R Soc Med       Date:  1993-02       Impact factor: 5.344

Review 5.  Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.

Authors:  D M Newnham
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation.

Authors:  A Flatt; J Crane; G Purdie; T Kwong; R Beasley; C Burgess
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

Review 9.  Risks versus benefits of inhaled beta 2-agonists in the management of asthma.

Authors:  B J Lipworth
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

10.  Safety of daily albuterol in infants with a history of bronchospasm: a multi-center placebo controlled trial.

Authors:  James A Hedrick; James W Baker; Arthur B Atlas; Aftab A Naz; William R Lincourt; Roopa Trivedi; Anna Ellworth; Angela M Davis
Journal:  Open Respir Med J       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.